In the case of hematopoietic tumors, CXCR4 antagonists, such as AMD3100 and AMD3465, potentiated the clinical efficacy of conventional therapies by mediating the trafficking of tumor cells from the bone marrow milieu. The gene discussed is CXCR4; the disease is neoplasm.